Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €40.27 EUR
Change Today +0.78 / 1.98%
Volume 0.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:28 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€39.07
Previous Close
€39.49
Day High
€40.44
Day Low
€39.07
52 Week High
03/16/15 - €43.94
52 Week Low
05/22/14 - €23.36
Market Cap
1.9B
Average Volume 10 Days
0.3
EPS TTM
--
Shares Outstanding
48.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of US Sales and Services
Total Annual Compensation: $375.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. Reaches Agreement in Principle with the U.S. Department of Justice to Settle OIG Matter

NuVasive, Inc. announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ) related to the previously disclosed subpoena issued to the Company in 2013 by the Office of Inspector General of the Department of Health and Human Services (OIG). Subject to completion of a definitive written settlement agreement, the company has agreed to pay $13.8 million, including fees, to the United States to resolve this matter. The company does not currently anticipate entering into a corporate integrity agreement with the OIG as part of the settlement. Finalizing the written settlement agreement could take several months.

NuVasive, Inc. to Report Q1, 2015 Results on May 04, 2015

NuVasive, Inc. announced that they will report Q1, 2015 results After-Market on May 04, 2015

NuVasive, Inc., Q1 2015 Earnings Call, May 04, 2015

NuVasive, Inc., Q1 2015 Earnings Call, May 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €40.27 EUR +0.78

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $51.23 USD +1.07
Globus Medical Inc $23.86 USD +0.56
Integra LifeSciences Holdings Corp $65.34 USD -0.14
Masimo Corp $34.60 USD +0.43
Thoratec Corp $39.96 USD -0.18
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.